Stroke News and Research

RSS

A stroke is a medical emergency. Strokes happen when blood flow to your brain stops. Within minutes, brain cells begin to die. There are two kinds of stroke. The more common kind, called ischemic stroke, is caused by a blood clot that blocks or plugs a blood vessel in the brain. The other kind, called hemorrhagic stroke, is caused by a blood vessel that breaks and bleeds into the brain. "Mini-strokes" or transient ischemic attacks (TIAs), occur when the blood supply to the brain is briefly interrupted.

Effectiveness of VSEL stem cells in regenerative medicine demonstrated at the ASH meeting

NeoStem, Inc. (NYSE Amex: NBS), which is a leading provider of pre-disease adult stem cell collection, processing and long-term storage services, and holds the exclusive, worldwide license to VSEL(TM) technology that uses very small embryonic-like stem cells isolated from peripheral blood, announced today that five posters and two oral presentations at the prestigious American Society of Hematology (ASH) Annual Meeting in New Orleans in early December demonstrated the basic cellular mechanisms of very small embryonic-like stem cells.

21 Dec 2009

Headache on rare occasions can be a warning sign of potentially serious disorder

Headaches are extremely common. Almost everyone has experienced a severe headache at least once in his or her lifetime. In most cases, headaches are minor nuisances that resolve within a short time. However, a headache can on rare occasions be the warning sign of a potentially serious disorder that requires immediate medical attention.

19 Dec 2009

Study provides new definition on dyslexia

Contrary to popular belief, some very smart, accomplished people cannot read well. This unexpected difficulty in reading in relation to intelligence, education and professional status is called dyslexia, and researchers at Yale School of Medicine and University of California Davis, have presented new data that explain how otherwise bright and intelligent people struggle to read.

18 Dec 2009

JDRF to work with Johnson & Johnson to develop drug targets and pathways for treating diabetes

The Juvenile Diabetes Research Foundation, a leader in setting the agenda for diabetes research worldwide, said today that it will begin working with The Johnson & Johnson Corporate Office of Science and Technology, and its affiliates, to speed the development of drug targets and pathways to promote the survival and function of insulin-producing cells in people who have diabetes.

18 Dec 2009

Unigene Laboratories selects UGP281 lead peptide from obesity program for development

Unigene Laboratories, Inc. (http://www.unigene.com) announced today that it has selected a lead peptide compound, designated UGP281, from its obesity program for development.

18 Dec 2009

Avecia Biologics to be acquired by Merck

Merck & Co. Inc., (operating in the United Kingdom as MSD) and Avecia Investments Limited today announced that they have entered into a definitive agreement by which Merck will acquire the biologics business of the Avecia group through a Merck affiliate (Merck Sharp & Dohme (Holdings) Limited or "MSD"). Avecia Biologics is a contract manufacturing organization with specific expertise in microbial-derived biologics. Financial details of the transaction were not disclosed.

17 Dec 2009

Neurologist performs catheter procedure on stroke patient

Most strokes are caused by blood clots in brain vessels. Brain cells die when deprived of blood and oxygen. But if a patient gets to the hospital in time, fast treatment often can restore blood flow and minimize damage.

17 Dec 2009

Roche discloses results of two of eight taspoglutide T-emerge phase III studies in diabetes patients

Ipsen, an innovation-driven global specialty pharmaceutical group, today announced that its partner Roche has disclosed headline results of the fourth and fifth of eight T-emerge phase III studies in patients with diabetes for taspoglutide, the first once weekly glucagon-like peptide-1 (GLP-1) analogue based on a human sequence.

17 Dec 2009

Discovery of common single-letter variant in SNP links parental origin to risk of T2D

Scientists at deCODE genetics, Inc. publish in the journal Nature the discovery of a version of a common single-letter variant in the sequence of the human genome (SNP) with a major impact on susceptibility to type 2 diabetes (T2D).

17 Dec 2009

RRE-90 score: A new web-based tool to predict recurrent stroke risk

Scientists have developed a new web-based tool that may better predict whether a person will suffer a second stroke within 90 days of a first stroke, according to research published in the December 16, 2009, online issue of Neurology®, the medical journal of the American Academy of Neurology.

17 Dec 2009

FDA Advisory Committee votes against the approval of Tarceva

OSI Pharmaceuticals, Inc. and Genentech, Inc., a wholly owned member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 12 to one recommending against approval of the daily pill Tarceva® (erlotinib) for first-line maintenance use in people with advanced or metastatic non-small cell lung cancer (NSCLC) whose cancer has not progressed (grown or spread) following first-line treatment with platinum-based chemotherapy.

17 Dec 2009

UC San Diego Medical Center performs complex surgery on brain lesion

Over three decades, a world-recognized medical team at UC San Diego Medical Center has spurred the evolution of a complex surgery to destroy dangerous clusters of arteries and veins in the brain. Integrating innovative approaches in radiology, anesthesia, and surgery, the team has perfected a method to systematically starve these abnormal brain lesions, artery by artery, vein by vein.

17 Dec 2009

Arizona State University and Mayo Clinic team up to explore metabolic syndrome

Arizona State University and Mayo Clinic in Arizona are joining forces in a partnership to investigate metabolic syndrome - a cluster of high-risk medical factors that include increased blood pressure, elevated insulin levels, excess body fat and abnormal cholesterol levels, which can lead to heart disease, stroke and diabetes.

16 Dec 2009

AstraZeneca's CRESTOR receives favorable vote from FDA Advisory Committee

The U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) today voted 12 yes, 4 no, and 1 abstention that AstraZeneca has established sufficient benefit to offset the observed risks to support the use of CRESTOR®

16 Dec 2009

Study suggests physical activity influences depression and fatigue by increasing self-efficacy

Physical activity is known to reduce depression and fatigue in people struggling with chronic illness. A new study indicates that this effect stems from an individual's sense of mastery over - or belief in his or her ability to achieve - certain physical goals.

16 Dec 2009

University of Florida obtains stimulus grant to establish ataxia consortium

University of Florida neurologists are trying to change that with the help of a $1 million Challenge grant from the National Institute of Neurological Disorders and Stroke to establish a nationwide network of physician-scientists with expertise in clinical ataxia research.

16 Dec 2009

Low plasma CETP activity associated with increased risk of heart disease, says study

Although seen as a potential heart disease therapy, raising high-density lipoprotein (HDL) cholesterol levels by inhibiting activity of a transfer protein may not be effective, a new study suggests.

16 Dec 2009

AstraZeneca, UVa announce collaboration in development of new treatments for CAD and PAD

AstraZeneca and the University of Virginia (UVa) in Charlottesville, today announced that they have entered into a strategic research collaboration to enhance development of new treatments primarily for coronary artery disease (CAD) with a secondary focus on peripheral vascular disease (PAD).

15 Dec 2009

Intensive medical therapy may benefit patients with asymptomatic plaque buildup

Intensive medical therapy, including aggressive control of blood pressure and cholesterol levels, for patients with asymptomatic plaque buildup in their carotid arteries (which supply blood to the brain) appears to be associated with reduced rates of cardiovascular events and reduced risk of microemboli (microscopic-sized blood clots) in the brain arteries, according to a report posted online today that will appear in the February 2010 print issue of Archives of Neurology, one of the JAMA/Archives journals.

15 Dec 2009

Phase III clinical trial evaluating darusentan misses its co-primary efficacy endpoints

Gilead Sciences, Inc. today announced that DAR-312 (DORADO-AC), a Phase III clinical trial evaluating darusentan, the company’s endothelin receptor antagonist (ERA) for the treatment of resistant hypertension, did not achieve its co-primary efficacy endpoints of change from baseline to week 14 in trough sitting systolic blood pressure (SBP) and diastolic blood pressure (DBP) compared to placebo.

15 Dec 2009

Stroke News and Research

Further Reading

Effectiveness of VSEL stem cells in regenerative medicine demonstrated at the ASH meeting

Headache on rare occasions can be a warning sign of potentially serious disorder

Study provides new definition on dyslexia

JDRF to work with Johnson & Johnson to develop drug targets and pathways for treating diabetes

Unigene Laboratories selects UGP281 lead peptide from obesity program for development

Avecia Biologics to be acquired by Merck

Neurologist performs catheter procedure on stroke patient

Roche discloses results of two of eight taspoglutide T-emerge phase III studies in diabetes patients

Discovery of common single-letter variant in SNP links parental origin to risk of T2D

RRE-90 score: A new web-based tool to predict recurrent stroke risk

FDA Advisory Committee votes against the approval of Tarceva

UC San Diego Medical Center performs complex surgery on brain lesion

Arizona State University and Mayo Clinic team up to explore metabolic syndrome

AstraZeneca's CRESTOR receives favorable vote from FDA Advisory Committee

Study suggests physical activity influences depression and fatigue by increasing self-efficacy

University of Florida obtains stimulus grant to establish ataxia consortium

Low plasma CETP activity associated with increased risk of heart disease, says study

AstraZeneca, UVa announce collaboration in development of new treatments for CAD and PAD

Intensive medical therapy may benefit patients with asymptomatic plaque buildup

Phase III clinical trial evaluating darusentan misses its co-primary efficacy endpoints

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News